Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial
暂无分享，去创建一个
W. Klapper | E. Hoster | O. Casasnovas | P. Feugier | H. Kluin-Nelemans | M. André | L. Obéric | M. Dreyling | V. Ribrag | J. Walewski | G. Damaj | C. Thieblemont | M. Gomes da Silva | M. Delfau-Larue | L. Fischer von Weikersthal | S. le Gouill | M. Taszner | A. Marín-Niebla | V. Safar | R. Boersma | I. Houtenbos | N. Daguindau | M. Haenel | Fernando Carcinero